Details of Drug Interaction | MecDDI

Drug General Information (ID: DDIX3MBKC7)
Drug Name			Warfarin		Drug Info		Miconazole		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Anticoagulants				Antifungal Agents
Structure

Mechanism of Warfarin-Miconazole Interaction (Severity Level: Major)
CYP450 enzyme inhibition Click to Show/Hide Mechanism Graph

Drug Name		Warfarin				Miconazole
Mechanism		CYP450 2C9 substrate				CYP450 2C9 inhibitor
Key Mechanism Factor 1
		Factor Name		Cytochrome P450 2C9				× Structure Sequence MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDISKSLTNLSKVYGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKKWKEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICSIIFHKRFDYKDQQFLNLMEKLNENIKILSSPWIQICNNFSPIIDYFPGTHNKLLKNVAFMKSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGTETTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYIDLLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNFKKSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASVPPFYQLCFIPV
		Gene Name		CYP2C9
		Uniprot ID		CP2C9_HUMAN
		KEGG Pathway		hsa:1559
		Protein Family		Cytochrome P450 family
		Protein Function		A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids and steroids (PubMed:7574697, PubMed:9866708, PubMed:9435160, PubMed:12865317, PubMed:15766564, PubMed:19965576, PubMed:21576599). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:7574697, PubMed:9866708, PubMed:9435160, PubMed:12865317, PubMed:15766564, PubMed:19965576, PubMed:21576599). Catalyzes the epoxidation of double bonds of polyunsaturated fatty acids (PUFA) (PubMed:7574697, PubMed:15766564, PubMed:19965576, PubMed:9866708). Catalyzes the hydroxylation of carbon-hydrogen bonds. Metabolizes cholesterol toward 25-hydroxycholesterol, a physiological regulator of cellular cholesterol homeostasis (PubMed:21576599). Exhibits low catalytic activity for the formation of catechol estrogens from 17beta-estradiol (E2) and estrone (E1), namely 2-hydroxy E1 and E2 (PubMed:12865317). Catalyzes bisallylic hydroxylation and hydroxylation with double-bond migration of polyunsaturated fatty acids (PUFA) (PubMed:9866708, PubMed:9435160). Also metabolizes plant monoterpenes such as limonene. Oxygenates (R)- and (S)-limonene to produce carveol and perillyl alcohol (PubMed:11950794). Contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenytoin, tolbutamide and losartan (PubMed:25994031). Click to Show/Hide
Mechanism Description		Decreased metabolism of Warfarin caused by Miconazole mediated inhibition of CYP450 enzyme

Recommended Action
Management		Patients receiving warfarin or other oral anticoagulants should be closely monitored during concomitant therapy with miconazole. The INR should be checked frequently and anticoagulant dosage adjusted accordingly, particularly following initiation or discontinuation of miconazole therapy in patients who are stabilized on their anticoagulant regimen. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools. Some authorities consider the use of oral miconazole with warfarin to be contraindicated. Although vaginally administered miconazole is generally less than 2% absorbed in healthy women of childbearing age, increased absorption may occur in the presence of atrophic vaginal epithelium. Therefore, the same precaution is applicable when vaginal formulations of miconazole is prescribed to women receiving oral anticoagulant therapy.

References
1	Ariyaratnam S, Thakker NS, Sloan P, Thornhill MH "Potentiation of warfarin anticoagulant activity by miconazole oral gel." BMJ 314 (1997): 349. [PMID: 9040331]
2	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
3	Colquhoun MC, Daly M, Stewart P, Beeley L "Interaction between warfarin and miconazole oral gel." Lancet 1 (1987): 695-6. [PMID: 2882124]
4	Devaraj A, O'Beirne JP, Veasey R, Dunk AA "Interaction between warfarin and topical miconazole cream." BMJ 325 (2002): 77. [PMID: 12114237]
5	Evans J, Orme DS, Sedgwick ML, Youngs GR "Treating oral candidiasis: potentially fatal." Br Dent J 182 (1997): 452. [PMID: 9231515]
6	Gutierrez MA, Olalla I, Muruzabal MJ, Ortiz M, Peralta FG "Miconazole oral gel enhances acenocoumarol anticoagulant activity. Report of three cases." Eur J Clin Pharmacol 52(Suppl) (1997): A132. [PMID: 10084413]
7	Marco M "Retroperitoneal haematoma and small bowel intramural haematoma caused by warfarin and miconazole interaction." Int J Oral Maxillofac Surg 27 (1998): 485. [PMID: 9869294]
8	Niwa T, Shiraga T, Takagi A "Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, CYP3A4 activities in human liver microsomes." Biol Pharm Bull 28 (2005): 1805-8. [PMID: 16141567]
9	O'Reilly RA, Goulart DA, Kunze KL, et al "Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects." Clin Pharmacol Ther 51 (1992): 656-67. [PMID: 1611805]
10	Ortin M, Olalla JI, Muruzabal MJ, Peralta FG, Gutierrez MA "Miconazole oral gel enhances acenocoumarol anticoagulant activity: A report of three cases." Ann Pharmacother 33 (1999): 175-7. [PMID: 10084413]
11	Pemberton M, Sloan P, Ariyaratnam S, Thakker NS, Thornhill MH "Treating oral candidiasis: potentially fatal." Br Dent J 183 (1997): 87. [PMID: 9282448]
12	Pemberton MN, Sloan P, Ariyaratnam S, Thakker NS, Thornhill MH "Derangement of warfarin anticoagulation by miconazole oral gel." Br Dent J 184 (1998): 68-9. [PMID: 9489213]
13	Shenfield GM, Page M "Potentiation of warfarin action by miconazole oral gel." Aust N Z J Med 21 (1991): 928. [PMID: 1818557]
14	Thirion DJ, Farquhar Zannetti LA "Potentiation of warfarin's hypoprothrombinemic effect with miconazole vaginal suppositories." Pharmacotherapy 20 (2000): 98-9. [PMID: 10641982]
15	Visser LE, Penning-Van Beest FJ, Kasbergen AA, et al. "Overanticoagulation associated with combined use of antifungal agents and coumarin anticoagulants." Clin Pharmacol Ther 71 (2002): 496-502. [PMID: 12087353]
16	Watson PG, Lochan RG, Redding VJ "Drug interaction with coumarin derivative anticoagulants." Br Med J 285 (1982): 1045-6. [PMID: 6812734]
17	Wells PS, Holbrook AM, Crowther NR, Hirsh J "Interactions of warfarin with drugs and food." Ann Intern Med 121 (1994): 676-83. [PMID: 7944078]